jueves, 28 de julio de 2011


Current recommendations for treatment of severe toxic alcohol poisonings.


Réanimation Médicale et Toxicologique, Hôpital Lariboisière, 2 rue Ambroise Paré, 5010 Paris, France. bruno-megarbane@wanadoo.fr


BACKGROUND: Ethylene glycol (EG) and methanol are responsible for accidental, suicidal, and epidemic poisonings, resulting in death or permanent sequelae. Toxicity is due to the metabolic products of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase. Conventional management of these intoxications consists of ethanol and hemodialysis. Fomepizole, a potent ADH inhibitor, has largely replaced antidotal ethanol use in France and two recent prospective U.S. trials definitively established its efficacy. Fomepizole appears safer than ethanol and while no comparative study of efficacy exists, fomepizole is recommended as the first-line antidote. FOCUS: Fomepizole, administered early in EG intoxication, prevents renal injury. In the absence of renal failure, EG clearance is rapid, avoiding the need for prolonged fomepizole administration. The long elimination half-life of methanol poisonings, with absent hemodialysis, necessitates prolonged administration of fomepizole. In the U.S. trials, patients were dialyzed when plasma EG or methanol concentrations were >/=0.5 g/l. However, EG-poisoned patients treated with fomepizole prior to the onset of significant acidosis may not require hemodialysis. Indeed, fomepizole may also obviate the need for hemodialysis in selected methanol-poisoned patients, in the absence of neurological and ocular impairment or severe acidosis. When dialysis is indicated, 1 mg.kg.h continuous infusion of fomepizole should be provided to compensate for its elimination. CONCLUSIONS: Fomepizole is an effective and safe first-line recommended antidote for EG and methanol intoxication. In selected patients, fomepizole may obviate the need for hemodialysis.

abacavir en metanol intoxicacion

abacavir un aniretroviral usado en flush y sida util en intoxicacion por metanol


fomepizol usado en intoxicacion por etanol es un inhibidor de la deshidrogenasa alcoholica

martes, 12 de julio de 2011

criterios para lupus y otras a pruebas a pedir

diagnostic criteria in SLE, presented in the "SOAP BRAIN MD" acronym:
  • Serositis - Pleurisy, pericarditis on examination or diagnostic ECG or imaging
  • Oral ulcers - Oral or nasopharyngeal, usually painless; palate is most specific
  • Arthritis - Nonerosive, two or more peripheral joints with tenderness or swelling
  • Photosensitivity - Unusual skin reaction to light exposure
  • Blood disorders - Leukopenia (< 4 X 103 cells/µL on more than one occasion), lymphopenia (< 1500 cells/µL on more than one occasion), thrombocytopenia (< 100 X 103 cells/µL in the absence of offending medications), hemolytic anemia
  • Renal involvement - Proteinuria (>0.5 g/d or 3+ positive on dipstick testing) or cellular casts
  • ANAs - Higher titers generally more specific (>1:160); must be in the absence of medications associated with drug-induced lupus
  • Immunologic phenomena - dsDNA; anti-Smith (Sm) antibodies; antiphospholipid antibodies (anticardiolipin immunoglobulin G [IgG] or immunoglobulin M [IgM] or lupus anticoagulant); biologic false-positive serologic test results for syphilis, lupus erythematosus (LE) cells (omitted in 1997)
  • Neurologic disorder - Seizures or psychosis in the absence of other causes
  • Malar rash - Fixed erythema over the cheeks and nasal bridge, flat or raised
  • Discoid rash - Erythematous raised-rimmed lesions with keratotic scaling and follicular plugging, often scarring

In patients with high clinical suspicion or high ANA titers, additional testing is indicated. This commonly includes evaluation of antibodies to dsDNA, complement, and ANA subtypes such as Sm, SSA, SSB, and ribonucleoprotein (RNP) (often called the ENA panel). Screening laboratory studies to diagnose possible SLE should include a CBC count with differential, serum creatinine, urinalysis with microscopy, ANA, and, perhaps, basic inflammatory markers. The following are autoantibody tests used in the diagnosis of SLE:[24]

  • ANA - Screening test; sensitivity 95%; not diagnostic without clinical features
  • Anti-dsDNA - High specificity; sensitivity only 70%; level variable based on disease activity
  • Anti-Sm - Most specific antibody for SLE; only 30-40% sensitivity
  • Anti-SSA (Ro) or Anti-SSB (La) - Present in 15% of patients with SLE and other connective-tissue diseases such as Sjögren syndrome; associated with neonatal lupus
  • Anti-ribosomal P - Uncommon antibodies that may correlate with lupus cerebritis
  • Anti-RNP - Included with anti-Sm, SSA, and SSB in the ENA profile; may indicate mixed connective-tissue disease with overlap SLE, scleroderma, and myositis
  • Anticardiolipin - IgG/IgM variants measured with enzyme-linked immunoassay (ELISA) among the antiphospholipid antibodies used to screen for antiphospholipid antibody syndrome
  • Lupus anticoagulant - Multiple tests (eg, Direct Russell Viper Venom test) to screen for inhibitors in the clotting cascade in antiphospholipid antibody syndrome
  • Coombs test - Coombs test–positive anemia to denote antibodies on RBCs
  • Anti-histone - Drug-induced lupus ANA antibodies often this type (eg, with procainamide or hydralazine; perinuclear antineutrophil cytoplasmic antibody [p-ANCA]–positive in minocycline-induced drug-induced lupus)

Other laboratory tests used in the diagnosis of SLE include the following:

  • Inflammatory markers: Levels of inflammatory markers, including the erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), may be elevated in any inflammatory condition, including SLE. CRP levels change more acutely, and the ESR lags behind disease changes.
  • Complement levels: C3 and C4 levels are often depressed in patients with active SLE because of consumption by immune complex–induced inflammation. In addition, some patients have congenital complement deficiency that predisposes them to SLE.
  • A CBC count may help to screen for leukopenia, lymphopenia, anemia, and thrombocytopenia, and urinalysis and creatinine studies may be useful to screen for kidney disease.
  • Liver test results may be mildly elevated in acute SLE or in response to therapies such as azathioprine or nonsteroidal anti-inflammatory drugs (NSAIDS).
  • Creatinine kinase levels may be elevated in myositis or overlap syndromes.

lupus pruebas a pedir

Immunologic phenomena - dsDNA; anti-Smith (Sm) antibodies; antiphospholipid antibodies (anticardiolipin immunoglobulin G [IgG] or immunoglobulin M [IgM] or lupus anticoagulant); biologic false-positive serologic test results for syphilis, lupus erythematosus (LE) cells (omitted in 1997)

contro agresivo de glucosa coon infusion de insulina en sica

mejora el pronostico el control intensivo de la glucosa em pacientes con sica? O es  la hiperglicemia simplemente un marcador de eventos adversos?.
parececiera que seria suficiente glucosa menor de 180